Cellectis S.A.
corporate_fare Company Profile
Cellectis S.A. (NASDAQ:CLLS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for CLLS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-14, rated 8/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CLLS spans 6-K, 20-F.
Recent high-impact activity:
- Cellectis Pivots to In Vivo Gene Editing, Exits CAR-T Programs
- Cellectis Q2 2026: Cash Runway into Q4 2027, Lasme-cel Pivotal Data Readout Expected Q4 2026
- Shareholders Approve Broad Dilutive Capital Raise Authorizations and ATM Program
- Cellectis Reports Strong Phase 1 Data for Lasme-cel (100% ORR) and Promising Eti-cel Results at EHA
- Cellectis's CAR-T Therapy Lasme-cel Receives FDA RMAT Designation for r/r B-ALL
Financial Snapshot
Short Interest & Short Volume
2.35 days to coverFINRA reported short interest of 488,061 shares in CLLS as of the September 15, 2026 settlement, a 68.5% increase from the prior period — about 2.4 days to cover at its recent average daily volume. On October 2, 2026, 29.3% of CLLS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CLLS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-25.
Broad Dilutive Capital Raise Authority Granted · At-The-Market (ATM) Program Authorized
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
CLLS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.